IBCN 2017: Building on past failures - new approaches to clinical trials for muscle-invasive bladder cancer

Lisbon, Portugal (UroToday.com) Walter Stadler from University of Chicago, Chicago, IL presented a review of prior failures to clinical trials. New drugs with new mechanism of action do not alter clinical trial designs. The hypothesis is systemic therapy improved outcomes because when added to local therapy improved outcomes among patients with muscle-invasive bladder cancer (MIBC). Neither the hypothesis not the objective are dependent on timing of chemotherapy administration. Defining endpoints prior to starting a trial is critical. Proper patient selection and stratification important in addition to sample size and power of the study. A highly inclusive versus highly selective population needs to be taken into account. With a multitude of new biomarkers and refined criteria, clinical trials need to focus on the basics to increase feasibility and meaningful results of results.

Speaker(s): Walter Stadler, University of Chicago, Chicago, IL

Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., at the International Bladder Cancer Network - October 21, 2017- Lisbon, Portugal

Login